<img src="https://ml.globenewswire.com/Resource/Download/4e983dfa-f169-46a5-ba21-ed1d05a90830?size=2" nborder="0" align="left" hspace="5" vspace="5" title="sureNano_logo.png" alt="SureNano Science Ltd."/>Disseminated on behalf of <a href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7Ul2hqbHCHaWcfCUsKhOWzwoP9SuR_aeDf8l090dT4K3sY8exXfiz7epmtp2-DPlJh7WvnOuCdFMQ-W_TNbcXTRf9MOfTIw9NIx92NnzS31nYpRp68eteJ9c3oCS5JvYEAMcTQvNZ4CamANFN_Aa1o7" rel="nofollow" target="_blank" title="">SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</a> and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via <a href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeLNwzZ3c-RYQ7VIXzkv_1VwGBqzLQMjG78V2R98WaECHZ5EgVY2A0H01iR6sygdcZg==" rel="nofollow" target="_blank" title="BioMedWire">BioMedWire</a> -- <a href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7XbbPvbGGf6Bn3Dp2Y5K1cz6DUrHI7qzoslBU91G3MHX_iUHW6ywVe6Lm0ujHjH8ZJNC4HcX0bCLV3EQqswHeNR7bWeHy03qkTI4zNgbUNA2y7HFfFh5NPN3hXqSSRDEpg=" rel="nofollow" target="_blank" title="SureNano Science Ltd.">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeBLJ7S-FkOqkz4sHyzt8qAXhNXJhJVqwMHU7Te8sptB2TR15U7xeu1_LS4EVX5PTRA==" rel="nofollow" target="_blank" title="BioMedWire">BioMedWire</a> (BMW), one of 75+ brands within the <a href="https://www.globenewswire.com/Tracker?data=kUTgsvxmkAHfyevvbWxaqgbnCq4Wl1XOrkqX2kHnEsEe3OzeNH2mbus7TMe5tKlHJLdCtLKR-UbyhbWupuULs1Zr5JbJwojIdslGsAjAKfXo0-1B4qNX5A-e3Z7ovZ4942xZVVLRtMgU1ROJx247rA==" rel="nofollow" target="_blank" title="Dynamic Brand Portfolio">Dynamic Brand Portfolio</a>@<a href="https://www.globenewswire.com/Tracker?data=ZAbimh84fXkKtfYW4mUxpsLXgovBatuGJwZ3nL65AV3S60IZPcFZsQpxMhbaPm4gTK7z9j0aRtmQBqRx9nhtc12w6vCaJfcrVsqfqXcPRRM=" rel="nofollow" target="_blank" title="IBN">IBN</a> (<a href="https://www.globenewswire.com/Tracker?data=RHM9PFay49SSE-WPWlpjRXJlx6YIT0o4TReXDhSVJTfMGyjeQQHzf-POmuQgMhyYb2aoo9xCh6doPmxWwQfOBk9ZZvmjrbKp1ZzAPXYx5x30375j14xTrKvhP5xWmvX-" rel="nofollow" target="_blank" title="InvestorBrandNetwork">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities,” please visit: <a href="https://www.globenewswire.com/Tracker?data=dCiJ6aWvR49tlf5ahEzOfL0IQi-1WbeufHpYeuGHjnR8weMkEc7sR7febRIkpA7-qtDTiu0fUHPpa9eTUgJG_0eiVQb-IXKxs1VwtmrnBLg=" rel="nofollow" target="_blank" title="">https://ibn.fm/F3zh0</a> Obesity and type 2 diabetes mellitus (“T2DM”) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd., which through its subsidiary GlucaPharm Inc. is developing a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history.  About SureNano Science Ltd. SureNano Science Ltd. (CSE: SURE) is a Canadian life sciences company focused on acquiring, developing and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. SureNano Science Ltd. has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential noninjectable delivery (refer to press release dated <a href="https://www.globenewswire.com/Tracker?data=2hyLTLtvR99ja8j7rzAPKglPoET5snrbZ7iLZ_MYyLLcZzGvmto-f49GNUr8LljkoRjvkYYEA-2zs8XjTksd07Fx-chi5493gW2MFTgLlKEnP5NTX60j_yJ0PJvbkC3v" rel="nofollow" target="_blank" title="">February 23, 2026</a>). The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease. For more information, visit the company’s website at <a href="https://www.globenewswire.com/Tracker?data=oMG-8vzE4IdJ2swTl8bsZv-3MbLIywLbsupnYWuALX1Wspgyolaky4UiKNG3TnMf8OICYsR3B-axBIikc_mpHbQN0FY9E_wMS_KDih-y0yc=" rel="nofollow" target="_blank" title="www.SureNano.com">www.SureNano.com</a>. NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at <a href="https://www.globenewswire.com/Tracker?data=dCiJ6aWvR49tlf5ahEzOfAj3vGMVzu97SWPMIEELzQXFMiVCEDmuwDA8QuAm7UZmNnjC5QpCLXJoAMasQ5L1ZXPQ32mUt4rjhB4bVULXaHs=" rel="nofollow" target="_blank" title="">https://ibn.fm/SURNF</a> About BioMedWire <a href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeIi-SqoX9zYZ57bE0GL_jdIvCb_yHYcVx2S9K7Dntt0bmFv00XsDa3sSdz_XSk2a85oO3Yjuf_BGbHkrs8SRoog=" rel="nofollow" target="_blank" title="BioMedWire">BioMedWire</a> (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the <a href="https://www.globenewswire.com/Tracker?data=kUTgsvxmkAHfyevvbWxaqgbnCq4Wl1XOrkqX2kHnEsGl_O99zzm8hcntS7WExfpJGfjbHZew5UHQv27FyMUcTP5PMSBtcmeKJfiFOfkdDaTI050ZPiga0hYsx6xIEjvcBzgG3GZ_SiR9jvsCp9risJvCY8iTOQnKzUtxnC8xsK4=" rel="nofollow" target="_blank" title="">Dynamic Brand Portfolio</a>@<a href="https://www.globenewswire.com/Tracker?data=xa2CRPuZ9yYzbOG9fcVPVXFwIcDKYinZHyoC4-JdbOpKaw9tYZuZh0E4DC6W81Lx337tlVPzBxOqhBNikTQpFiUDllbCk-OIV083u48N9Zo=" rel="nofollow" target="_blank" title="">IBN</a> that delivers: (1) access to a vast network of wire solutions via <a href="https://www.globenewswire.com/Tracker?data=RHM9PFay49SSE-WPWlpjRZ2sIIVwGozuzC-oOlwjqdoYiLO93y7sDL3sp32QV-1WpRxzOR__q79ZScPI-12jhf54DvTwPDeSr_w5Ll52QHc=" rel="nofollow" target="_blank" title="InvestorWire">InvestorWire</a> to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and <a href="https://www.globenewswire.com/Tracker?data=LBU9XCEycBo2TqBMmhMTPxkWoCQXSx8ztzX7oZceLgTuZYMBttUrpsuOPv60XizmNKveCupPFMDELY--CQMbeyOIKZb8gjOprRYd5jnkldt9i7LrQegUuQlZMRY88s6ROSlTQcnk47u-4plwH3PDMVbQsirguwMq2-SPJgSVQU5uvwXJIaXG4ORInqPKnAKKZaXOx-wyv4iYAN0IyMSE-SfCydowNZsLwKJ_7a_YF8Y=" rel="nofollow" target="_blank" title="editorial syndication to 5,000+ outlets">editorial syndication to 5,000+ outlets</a>; (3) <a href="https://www.globenewswire.com/Tracker?data=8iNKDBygyYn_ZWSsW7iLjoz3XtphRcpN7HkgYc5cMg6gO2baRK4sxLhP_AAJC8jCLfUOtX4sFYPr6V75bXVJw2A9bXzVWHc2xGsqTQhHEC8FHZntB680nPXgjBg7_YbRwJLf48VZ4tkWbkHw4htqmCq_h6CYgCszGJOUQiOg48d0p9fjahzVhQnMSkyjC0Jq" rel="nofollow" target="_blank" title="press release enhancement">press release enhancement</a> to ensure maximum impact; (4) <a href="https://www.globenewswire.com/Tracker?data=mc9nMlYVyWrbJpOWvMZEslifT6KtMMJhrKIFmVk1wjm5N-FvDvf1E0ErAii3PZUm3BrD1wnAV4uZZNo2bu8FApRjvYzsY2Yrh3wLFixyZzj8JyzVy0hU-SUTrVmuhos_yqB2ao9v5rc8dVfOlqttdA==" rel="nofollow" target="_blank" title="social media distribution">social media distribution</a> via IBN to millions of social media followers; and (5) a full array of tailored <a href="https://www.globenewswire.com/Tracker?data=MO8qJfdFUGykX6G0g22WnOPxnYfj9IScRDsHxdllxIP0TcpovgToY7tpUjtM4Y8gvjTpQh-NpgPkMRXvij8ubeYv7gLOKjfIgGyOOoo748xAIAlANbAAp0FgjzbZrNyN7TGd308wrt45sH9eKyKeaA==" rel="nofollow" target="_blank" title="corporate communications solutions">corporate communications solutions</a>. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=dCiJ6aWvR49tlf5ahEzOfCBNA1WE0yODPdZtp5o5r2rCVcW2rmPGPV7xTtsq_hmapMDPp_xSDCdXdgNqfiupdb6TSqVIYad7ErOE14cOfFF42IShvoYcoYX0MZC7d9uI" rel="nofollow" target="_blank" title="">https://www.BioMedWire.com</a> DISCLAIMER: <a href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeNC8N3xoQYSKqQFZqQd4HIWC5kLRhPBY-YOEb9FoIoygL3vA8nmScVfF4e5YNzfLbs9U19BNcUTeJRkkQc7PLg0=" rel="nofollow" target="_blank" title="">BioMedWire (BMW)</a> is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: <a href="https://www.globenewswire.com/Tracker?data=dCiJ6aWvR49tlf5ahEzOfCBNA1WE0yODPdZtp5o5r2qwz7OexTOonQWHe4NFKoC3IrK_i3Y82KIKStcdXE82in7vCguvBaBradL7sBQgpytYiy2YwpyDFYMygPJoKuGkTPCr4fFIl_QrGGsv3TzRtg==" rel="nofollow" target="_blank" title="">https://www.BioMedWire.com/Disclaimer</a> BioMedWire Austin, Texas <a href="https://www.globenewswire.com/Tracker?data=v0M2VOper120Rvq3puXrItghUG00S5s_mW4651g4Z3XvmicAQB-Yjp7RRr4g34SwEYSAMW7hIRUGe-YNmhxKDK3tjuhpdYW5kqUJLPSt0PU=" rel="nofollow" target="_blank" title="www.BioMedWire.com">www.BioMedWire.com</a> 512.354.7000 Office <a href="https://www.globenewswire.com/Tracker?data=MzukcYiaTmKqysMqEUqGRFyuqq03P6XJA-lZU5e7oGtc7nddMjb5-f_LmPQcH0xPKfYDYckSu2TvFGq-BVWYeumycWT6CnaO1OF1PoXmxsE=" rel="nofollow" target="_blank" title="Editor@BioMedWire.com">Editor@BioMedWire.com</a> BioMedWire is powered by <a href="https://www.globenewswire.com/Tracker?data=aD50RYiGP6mX5_pXWvjDYZEi9db2-9W1dPkp94mDvYDl2E3yIbUF9J7AdK-cEkqpXluFFPj92QnaHYvPf3X9gLEbkYpEyTnZ_sXawXn9q4g=" rel="nofollow" target="_blank" title="IBN">IBN</a> <img alt="" src='https://ml.globenewswire.com/media/YTUxOTQ3MzYtYWU4Mi00YjQ1LTk1NGYtOTdjODVhNzYwMGNlLTUwMDE2MjQ3OS0yMDI2LTA1LTE0LWVu/tiny/SureNano-Science-Ltd-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn